Items Tagged ‘enazlutamide’

September 15th, 2014

FDA Approves Use of Xtandi for Chemotherapy Naïve Men With Advanced Prostate Cancer


The FDA approved the use of Xtandi® (enzalutamide) in men who have not yet received chemotherapy, significantly expanding the potential patient population eligible to be treated with the oral medicine.  Xtandi originally gained U.S. approval in 2012 for use in patients with castration-resistant prostate cancer that has spread beyond the prostate only after they had […]

View full entry

Tags: enazlutamide, hormone refractory, metastatic prostate cancer, Metastatic Stage IV (D) Prostate Cancer, News, PREVAIL trial, Prostate Cancer, Refactory/Recurrent Prostate Cancer, xtandi